Progress of immunotherapy of acute myelogenous leukemia
10.3760/cma.j.issn.1009-9921.2019.01.004
- VernacularTitle:急性髓系白血病免疫治疗新进展
- Author:
Ruihua MI
1
;
Fangfang YUAN
;
Xudong WEI
Author Information
1. 郑州大学附属肿瘤医院 河南省肿瘤医院血液科 450003
- Keywords:
Leukemia,myelogenous,acute;
Immunotherapy
- From:
Journal of Leukemia & Lymphoma
2019;28(1):12-16
- CountryChina
- Language:Chinese
-
Abstract:
Acute myelogenous leukemia (AML) is a highly heterogeneous malignant hematologic disease, and its clinical treatment mainly includes traditional chemotherapy, but the efficacy is limited and the patients with worse performance status and comorbidities can not be treated with chemotherapy. In recent years, immunotherapy has achieved certain curative effects in AML which shows a promising prospect. This review introduces immunotherapy of AML reported in 60th American Society of Hematology (ASH) Annual Meeting.
